Recent advances in immunotherapies for lupus nephritis.
Ontology highlight
ABSTRACT: Childhood-onset systemic lupus erythematosus (SLE) is characterized by increased rates of kidney involvement, termed lupus nephritis. Despite the significant morbidity and mortality associated with this disease, lupus nephritis trials have been plagued by repeated failures to meet clinical endpoints. However, improvements in trial design and the development of targeted approaches have begun to yield promising results, including two new FDA-approved lupus nephritis treatments since 2020. These include belimumab, a monoclonal antibody targeting the B cell survival cytokine BAFF (B cell activating factor), and voclosporin, a cyclosporin analog with improved pharmacokinetic characteristics. In this review, we will summarize the data supporting regulatory approval for these agents in lupus neph
SUBMITTER: Kaneko M
PROVIDER: S-EPMC10219838 | biostudies-literature | 2023 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA